×
The Standard e-Paper
Home To Bold Columnists
Kenya’s adoption of long-acting injectable lenacapavir is a major HIV prevention breakthrough, but its success will depend on public trust and dignity in delivery.
Lenacapavir, recently introduced in Kenya, is a long-acting HIV preventive medicine, not a vaccine, offering six-monthly protection through pre-exposure prophylaxis (PrEP).
Subscribe to our newsletter and stay updated on the latest developments and special offers!
Join